Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests $89
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests $335
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical data sheet

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  2. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  3. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  4. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  5. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  6. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  7. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  8. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  9. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  10. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  11. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  12. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  13. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  14. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  15. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  16. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  17. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  18. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  19. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  20. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  21. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  22. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  23. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  24. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  25. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  26. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  27. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  28. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  29. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  30. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  31. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  32. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  33. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  34. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  35. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  36. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  37. Pleuger C, et al. 2022. Elife. 11: . PubMed
  38. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  39. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  40. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  41. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  42. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  43. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  44. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  45. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  46. Rosain J, et al. 2023. Cell. 186:621. PubMed
  47. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  48. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  49. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  50. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  51. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  52. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  53. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  54. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  55. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  56. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  57. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  58. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  59. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  60. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  61. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  62. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  63. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  64. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  65. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  66. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  67. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  68. Zhao Y, et al. 2022. J Neurosci. . PubMed
  69. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  70. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  71. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  72. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  73. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  74. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  75. Han X, et al. 2022. Nutrients. 14:. PubMed
  76. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  77. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  78. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  79. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  80. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  81. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  82. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  83. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  84. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  85. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  86. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  87. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  88. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  89. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  90. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  91. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  92. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  93. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  94. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  95. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  96. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  97. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  98. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  99. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  100. Imai H, et al. 2023. iScience. 26:106822. PubMed
  101. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  102. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  103. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  104. Wu L, et al. 2023. Cell Res. . PubMed
  105. Cansever D, et al. 2023. Nat Immunol. . PubMed
  106. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  107. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  108. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  109. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  110. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  111. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  112. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  113. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  114. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  115. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  116. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  117. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  118. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  119. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  120. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  121. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  122. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  123. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  124. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  125. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  126. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  127. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  128. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  129. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  130. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  131. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  132. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  133. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  134. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  135. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  136. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  137. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  138. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  139. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  140. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  141. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  142. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  143. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  144. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  145. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  146. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  147. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  148. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  149. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  150. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  151. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  152. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  153. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  154. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  155. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  156. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  157. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  158. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  159. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  160. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  161. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  162. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  163. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  164. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  165. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  166. Woodruff MC, et al. 2022. Nature. :. PubMed
  167. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  168. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  169. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  170. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  171. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  172. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  173. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  174. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  175. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  176. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  177. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  178. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  179. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  180. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  181. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  182. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  183. Akiyama H, et al. 2020. J Virol. . PubMed
  184. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  185. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  186. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  187. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  188. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  189. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  190. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  191. Mills C, et al. 2022. Cells. 11:. PubMed
  192. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  193. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  194. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  195. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  196. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  197. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  198. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  199. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  200. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  201. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  202. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  203. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  204. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  205. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  206. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  207. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  208. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  209. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  210. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  211. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  212. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  213. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  214. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  215. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  216. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  217. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  218. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  219. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  220. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  221. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  222. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  223. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  224. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  225. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  226. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  227. Wang Z, et al. 2021. bioRxiv. . PubMed
  228. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  229. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  230. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  231. English KG, et al. 2022. Biomedicines. 10:. PubMed
  232. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  233. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  234. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  235. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  236. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  237. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  238. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  239. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  240. Woodruff M, et al. 2020. medRxiv. . PubMed
  241. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  242. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  243. Popay TM, et al. 2021. Elife. 10: . PubMed
  244. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  245. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  246. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  247. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  248. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  249. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  250. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  251. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  252. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  253. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  254. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  255. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  256. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  257. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  258. Elias G, et al. 2022. Elife. 11:. PubMed
  259. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  260. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  261. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  262. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  263. Ito Y, et al. 2018. Cell. 174:636. PubMed
  264. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  265. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  266. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  267. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  268. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  269. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  270. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  271. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  272. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  273. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  274. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  275. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  276. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  277. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  278. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  279. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  280. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  281. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  282. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  283. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  284. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  285. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  286. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  287. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  288. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  289. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  290. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  291. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  292. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  293. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  294. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  295. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  296. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  297. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  298. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  299. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  300. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  301. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  302. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  303. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  304. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  305. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  306. Wang Z, et al. 2021. Nature. 592:616. PubMed
  307. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  308. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  309. Dudek M, et al. 2021. Nature. 592:444. PubMed
  310. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  311. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  312. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  313. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  314. He Y, et al. 2022. Cells. 11:. PubMed
  315. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  316. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  317. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  318. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  319. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  320. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  321. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  322. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  323. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  324. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  325. Wang Z, et al. 2021. Nature. 595:426. PubMed
  326. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  327. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  328. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  329. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  330. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  331. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  332. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  333. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  334. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  335. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  336. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  337. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  338. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  339. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  340. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  341. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  342. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  343. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  344. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  345. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  346. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  347. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  348. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  349. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  350. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  351. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  352. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  353. Korin B, et al. 2020. Sleep. :43. PubMed
  354. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  355. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  356. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  357. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  358. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  359. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  360. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  361. Viant C, et al. 2020. Cell. 183:1298. PubMed
  362. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  363. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  364. Gaebler C, et al. 2020. bioRxiv. . PubMed
  365. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  366. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  367. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  368. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  369. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  370. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  371. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  372. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  373. Sibler E, et al. 2021. Cells. 10:. PubMed
  374. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  375. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  376. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  377. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  378. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  379. Spath S, et al. 2022. iScience. 25:104998. PubMed
  380. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  381. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  382. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  383. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  384. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  385. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  386. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  387. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  388. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  389. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  390. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  391. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  392. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  393. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  394. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  395. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  396. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  397. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  398. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  399. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  400. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 6    Revision Date: 09/16/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account